Every Form 4 that Emergent Biosolutions, Inc. (EBS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EBS filings page.
Emergent BioSolutions Inc. reported an insider stock sale by senior vice president Paul Anthony Williams. On July 1, 2026, he executed an open-market sale of 3,000 shares of common stock at a weighted average price of $8.40 per share, with individual sale prices ranging from $8.31 to $8.46. The transaction was made under a pre-arranged trading plan adopted on November 14, 2025 intended to comply with Rule 10b5-1. Following this sale, Williams directly holds 159,098 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Inc. senior vice president of the Products Business, Paul Anthony Williams, reported a routine tax-related share disposition. On the vesting and settlement of restricted stock units, 694 shares of common stock were withheld at $8.00 per share to cover associated tax obligations.
Following this withholding, Williams directly holds 162,098 shares of Emergent BioSolutions common stock. The transaction was not an open-market sale but a standard payment of tax liability using shares received from equity compensation.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported a routine tax-related share disposition. On the reported date, 3,964 shares of common stock were withheld at $8.00 per share to cover taxes tied to the vesting and settlement of restricted stock units, rather than being sold on the open market. After this withholding, Lindahl directly held 374,083 shares of common stock, indicating he retains a substantial equity position in the company.
Emergent BioSolutions Inc. executive Coleen Glessner reported a routine tax-related share disposition. On the vesting and settlement of restricted stock units, 2,018 shares of common stock were withheld to cover associated taxes at an indicated value of $8.00 per share. After this withholding, she directly holds 202,201 shares of Emergent BioSolutions common stock, so the filing reflects a compensation and tax event rather than an open-market trade.
Emergent BioSolutions Inc. Senior Vice President of Bioservices William Hartzel reported a routine tax-related share disposition. On June 8, 2026, 1,741 shares of common stock were withheld at $8.00 per share to cover taxes from the vesting and settlement of restricted stock units. After this withholding, Hartzel directly held 185,558 shares of Emergent BioSolutions common stock. This was not an open-market sale but an automatic tax-withholding mechanism tied to equity compensation.
Emergent BioSolutions director Sujata Tyagi reported a mix of stock awards and tax-related sales. On April 30, 2026, she received an annual grant of 25,344 restricted stock units and 11,296 stock options with a $7.99 exercise price, vesting in one year for continued board service. On May 1, 2026, she sold a total of 13,761 common shares in open-market trades at weighted average prices around the $8–$9 range under a pre-arranged Rule 10b5-1 trading plan to cover taxes from RSU vesting. Following these transactions, she continues to directly hold 100,563 common shares of Emergent BioSolutions.
Emergent BioSolutions director Donald W. DeGolyer reported both equity grants and tax-related share sales. On April 30, he received 25,344 restricted stock units as an annual board grant and 11,296 stock options with a $7.99 exercise price, both vesting one year after grant if he remains on the board.
In connection with RSUs that vested on April 29, he sold a total of 15,481 common shares in open-market transactions on May 1 under a pre-arranged Rule 10b5-1 trading plan to satisfy tax obligations. Following these sales, he directly holds 129,721 common shares, along with the newly granted unvested options.
Emergent BioSolutions director Keith Katkin reported both a sale and new equity awards. He sold 15,481 shares of common stock at a weighted average price of $8.28 per share under a Rule 10b5-1 trading plan to satisfy tax obligations from RSUs that vested on April 29, 2026. On the same date, he received an annual grant of 25,344 restricted stock units for board and committee service, which will vest the day before the one-year anniversary of the grant if he remains on the board. He also received 11,296 stock options with a $7.99 exercise price, expiring April 30, 2033, and reported holding 111,775 shares directly after these transactions.
Emergent BioSolutions Inc. reported that director Marvin L. White received equity compensation on April 30, 2026. He was granted 25,344 restricted stock units for Board and Committee service, each RSU representing one share of common stock upon vesting.
He also received 11,296 stock options, each allowing the purchase of one common share at an exercise price of $7.99 per share. Both the RSUs and options vest on the day prior to the one-year anniversary of the grant date, contingent on his continued board service. After these awards, he directly holds 113,839 common shares.
Emergent BioSolutions Inc. director John D. Fowler Jr. received equity compensation for Board and Committee service. He was granted 25,344 restricted stock units (RSUs), each representing one share of common stock that will vest on the day prior to the one-year anniversary of the grant date, as long as he remains on the board through that date. He was also granted 11,296 stock options to buy common shares at an exercise price of $7.99 per share, expiring on April 30, 2033, which vest on the same one-year schedule. Following the RSU grant, his direct common stock holdings increased to 30,350 shares.
Emergent BioSolutions Inc. reported that director Richard Ronald received equity awards as part of his board compensation. He was granted 25,344 restricted stock units, each representing one share of common stock upon vesting, for Board and Committee service.
He also received 11,296 stock options with an exercise price of $7.99 per share, expiring in 2033. Both the RSUs and options vest on the day prior to the one-year anniversary of the grant date, as long as he remains on the board. After these grants, he directly holds 123,761 common shares.
Emergent BioSolutions director Kathryn C. Zoon reported routine equity compensation and related share sales. On April 30, 2026, she received 25,344 restricted stock units for Board and Committee service and 11,296 stock options with a $7.99 exercise price, both vesting the day before the one-year grant anniversary, subject to continued board service.
On May 1, 2026, she sold a total of 17,202 shares of common stock in open-market transactions at weighted average prices of $8.36 and $8.97 per share under a Rule 10b5-1 trading plan dated May 16, 2025, to satisfy tax obligations from RSUs vesting on April 29, 2026. After these transactions, she directly holds 79,941 common shares.
Emergent BioSolutions director Neal Franklin Fowler received new equity awards as part of his annual board compensation. He was granted 25,344 restricted stock units, each representing one share of common stock that will vest the day before the one-year anniversary of the grant, if he remains on the board.
He also received stock options for 11,296 shares at an exercise price of $7.99 per share, vesting on the same schedule. After these awards, he directly holds 160,847 shares of common stock, plus the newly granted options. These are compensation grants, not open‑market purchases or sales.
Emergent BioSolutions Inc. director and Chairman Zsolt Harsanyi received equity compensation in the form of restricted stock units and stock options. He was granted 25,344 RSUs, each representing one share of common stock upon vesting, and 11,296 stock options with an exercise price of $7.99 per share. Both the RSUs and options vest on the day before the one-year anniversary of the grant date, contingent on his continued service on the board. Following these awards, Harsanyi directly holds 149,076 shares of Emergent BioSolutions common stock.
Williams Paul Anthony reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. Senior Vice President, Products Business, Paul Anthony Williams received a grant of 100,111 shares of common stock in the form of restricted stock units. This award was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an amendment to the 2006 Stock Incentive Plan, which stockholders granted on April 29, 2026.
The restricted stock units, granted under the Amended Stock Incentive Plan, vest in three annual installments beginning on the first anniversary of the approval date, assuming continued service with the company. After this grant, Williams directly holds 162,792 shares, and each restricted stock unit represents the right to receive one share of Emergent BioSolutions common stock, subject to adjustment under the grant terms.
Lowry Simon C reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. granted SVP, R&D, CMO Simon C. Lowry 100,111 shares of common stock in the form of restricted stock units. The award was approved by the Compensation Committee on March 2, 2026 and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service. Each unit entitles Lowry to receive one share of common stock, bringing his direct holdings to 177,914 shares after the grant.
Glessner Coleen reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. reported that EVP of Quality & Ethics and CPL, Coleen Glessner, received a grant of 100,111 restricted stock units of common stock at no cost. The grant was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an Amended Stock Incentive Plan, which stockholders approved on April 29, 2026.
The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming Ms. Glessner continues her service with the company. Each unit represents one share of common stock, and following this award she holds 204,219 shares of common stock directly.
Emergent BioSolutions reported that EVP and Chief Financial Officer Richard S. Lindahl acquired 162,680 shares of common stock through a restricted stock unit grant at no cash cost. The grant was approved by the Compensation Committee on March 2, 2026, and became effective after stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, contingent on continued service. Following this award, Lindahl directly holds 378,047 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Inc. reported that SVP and General Counsel Jessica Perl received a grant of 104,282 shares of common stock in the form of restricted stock units as compensation. The grant was approved by the board’s Compensation Committee on March 2, 2026 and became effective after stockholders approved an amended stock incentive plan on April 29, 2026.
The restricted stock units vest in three equal annual installments beginning on the first anniversary of the approval date, contingent on continued service. Each restricted stock unit converts into one share of common stock, bringing Perl’s direct holdings to 165,286 shares following this award.
Hartzel William reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. granted Senior Vice President of Bioservices William Hartzel 100,111 shares of Common Stock in the form of restricted stock units. The award was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an amended stock incentive plan.
Stockholders approved the Amended Stock Incentive Plan on April 29, 2026, allowing the grant to proceed. These restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service. After this grant, Hartzel directly holds 187,299 shares of common stock.
Emergent BioSolutions President and CEO Joseph C. Papa received a grant of 187,708 restricted stock units, approved by the Compensation Committee and stockholders under the company’s Amended Stock Incentive Plan. This equity award is a form of non-cash compensation and brings his direct holdings to 493,153 common shares.
The RSUs vest in three equal annual installments beginning on the anniversary of the approval date, assuming he continues serving at the company. Each restricted stock unit converts into one share of Emergent BioSolutions common stock upon vesting, aligning a portion of his compensation with future company performance.
Emergent BioSolutions Inc. senior vice president of Products Business Paul Anthony Williams reported an open-market sale of Common Stock. On April 1, 2026, he sold 4,000 shares at a weighted average price of $8.44 per share. The trades occurred within a price range of $8.34 to $8.54 and were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 14, 2025. Following this sale, Williams directly holds 62,681 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported the expiration of two employee stock option awards. Stock options for 20,321 shares and 19,963 shares expired unexercised pursuant to their terms, and the footnotes state that no value was received upon expiration.
Emergent BioSolutions Inc. reported that President and CEO Joseph C. Papa received an award of employee stock options covering 252,194 shares on March 3, 2026, at an exercise price of $0.00 per share. These options vest in three equal installments beginning the day prior to each anniversary of the grant date.
On March 5, 2026, 37,055 shares of common stock were withheld and disposed of to cover taxes tied to the vesting and settlement of performance stock units at a price of $8.44 per share, leaving Papa with 305,445 common shares directly owned.
FOWLER JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. director John D. Fowler Jr reported an equity award of 5,006 shares of common stock in the form of restricted stock units. The units were granted at a reference value of $8.99 per share and were issued under the company’s Stock Incentive Plan.
These 5,006 restricted stock units vest in three annual installments, beginning on the day prior to the anniversary of the grant date, assuming he continues serving the company. Each unit represents the right to receive one share of Emergent BioSolutions common stock, and Fowler now directly holds 5,006 shares following this grant.
Emergent BioSolutions SVP, R&D, CMO Simon C. Lowry reported two equity compensation transactions. On March 5, 2026, 10,636 shares of common stock were disposed of at $8.44 per share to cover taxes tied to vesting and settlement of restricted stock units, leaving 77,803 shares held directly. On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of $0.00 per share, with the options vesting in three equal installments beginning the day before each anniversary of the grant date, increasing his directly held options to 147,833.
Emergent BioSolutions senior vice president William Hartzel reported routine equity compensation transactions. On March 5, 2026, 9,493 shares of common stock were disposed of at $8.44 per share to cover taxes tied to restricted stock unit vesting, leaving him with 87,188 shares of common stock held directly.
On March 3, 2026, he received a grant of 44,834 employee stock options, increasing his directly held options to 259,545. The grant is scheduled to vest in three equal installments beginning on the day prior to each anniversary of the grant date.
Emergent BioSolutions Inc. reported insider equity activity by SVP and General Counsel Jessica Perl. She received a grant of 46,702 employee stock options at an exercise price of $0.00 per option on common stock. According to a footnote, these options vest in three equal installments beginning on the day prior to the anniversary date of the grant.
On a separate date, 6,465 shares of common stock were disposed of in a tax-withholding disposition at $8.44 per share, with a footnote explaining the shares were withheld to pay taxes associated with the vesting and settlement of restricted stock units. Following these transactions, Perl directly owned 61,004 common shares and held 142,647 stock options.
Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported two equity compensation transactions. On March 5, 2026, 9,397 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, leaving him with 66,681 common shares directly held.
On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of $0.00 per share, increasing his directly held options to 254,948. The options vest in three equal installments beginning on the day prior to the anniversary date of the grant.
Emergent BioSolutions EVP and CFO Richard S. Lindahl reported routine equity compensation and related tax withholding. On March 3, he acquired 72,856 employee stock options at an exercise price of $0.00 per share as a grant that vests in three equal installments beginning the day prior to each anniversary of the grant date. On March 5, 23,650 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, rather than through an open-market sale. After these transactions, he held 215,367 shares of common stock and 557,346 stock options directly.
Emergent BioSolutions EVP Coleen Glessner reported a stock option grant and a related tax-withholding share disposition. On March 3, she acquired 44,834 Employee Stock Options (right to buy common stock) as a grant with a stated price of $0.00 per option, which vest in three equal installments beginning on the day prior to each anniversary of the grant date.
On March 5, 8,199 shares of common stock were withheld and disposed of to cover taxes associated with the vesting and settlement of restricted stock units. After these transactions, she directly owned 104,108 shares of common stock and 294,447 stock options.
Emergent BioSolutions Inc. senior vice president Paul Anthony Williams reported a small share disposition related to equity compensation. On the reported date, 116 shares of common stock were withheld at $8.15 per share to cover taxes triggered by the vesting and settlement of restricted stock units. This was an automatic tax-withholding transaction, not an open-market trade, and left Williams with a direct holding of 76,078 common shares.
Emergent BioSolutions Inc. reported a routine insider equity transaction by its EVP and Chief Financial Officer, Richard S. Lindahl. On the reported date, 683 shares of common stock were disposed of at $8.15 per share to cover tax withholding tied to the vesting and settlement of restricted stock units. After this tax-withholding disposition, Lindahl directly owned 239,017 shares of Emergent BioSolutions common stock.
Emergent BioSolutions EVP Coleen Glessner reported a small share disposition related to taxes. On the vesting of restricted stock units, 313 shares of common stock were withheld at $8.15 per share to cover tax obligations. After this tax-withholding disposition, she directly owns 112,307 common shares.
Emergent BioSolutions Inc. senior vice president and general counsel Jessica Perl reported an automatic share withholding related to equity compensation. On February 9, 2026, 918 shares of common stock were withheld at $11.03 per share to pay taxes on vesting restricted stock units. After this tax withholding, she directly beneficially owns 67,469 shares of Emergent BioSolutions common stock.
Emergent BioSolutions executive Coleen Glessner reported equity award outcomes and related share movements. On February 6, 2026, she recorded a disposition of 28,847 shares of common stock at $10.92 per share linked to performance stock units granted under the company’s stock incentive plan.
The Compensation Committee certified the 2023–2025 performance stock units at 25% of target, resulting in an actual award of 9,615 shares of common stock, compared with 38,462 shares previously reported for that grant. She also had 2,852 shares withheld at $10.92 per share to cover taxes on vesting and settlement of restricted stock units.
Following these transactions, Glessner directly beneficially owns 112,620 shares of Emergent BioSolutions common stock.
Emergent BioSolutions SVP Paul Anthony Williams reported equity compensation outcomes and share movements. On February 6, 2026, he reported a disposition of 8,655 shares of common stock at $10.92 per share, leaving him with 77,216 shares directly held, then a further 1,022 shares were withheld at $10.92 to cover taxes tied to restricted stock unit vesting, resulting in 76,194 shares owned afterward.
The filing explains that these transactions relate to performance stock units granted under the company’s stock incentive plan. The compensation committee certified 2023–2025 PSU performance at 25% of target, leading to an actual award of 2,884 shares of common stock, below the 11,539 shares previously reported for that award cycle.
Emergent BioSolutions SVP, Bioservices William Hartzel reported routine equity award adjustments and tax withholding transactions in company stock. On February 6, 2026, 5,771 performance stock units tied to 2023–2025 goals were disposed of after the Compensation Committee certified performance at 25% of target, resulting in a smaller share payout than originally reported.
On the same date, 630 shares of common stock were withheld to cover taxes on vested restricted stock units. After these transactions, Hartzel directly owned 96,681 shares of Emergent BioSolutions common stock.
Emergent BioSolutions EVP and CFO Richard S. Lindahl reported equity award activity tied to performance stock units and tax withholding. On February 6, 2026, he disposed of 46,155 shares of common stock at $10.92 per share and had 245,342 shares beneficially owned immediately afterward.
The filing explains that 2023–2025 performance stock units under the company’s stock incentive plan were certified at 25% of target, resulting in an actual award of 15,384 shares of common stock. In a separate transaction the same day, 5,642 shares at $10.92 per share were withheld to cover taxes on vesting, leaving Lindahl with 239,700 directly owned shares.
Emergent BioSolutions reported an insider transaction by an officer serving as senior vice president of R&D and chief medical officer. On December 14, 2025, 3,543 shares of common stock were withheld at a price of $11.41 per share to pay taxes due when restricted stock units vested and settled.
After this tax withholding, the officer directly beneficially owns 88,439 shares of Emergent BioSolutions common stock.
Emergent BioSolutions director reported multiple stock transactions in the company’s shares. On December 5, 2025, the director exercised 25,748 stock options at an exercise price of $5.02 per share, receiving the same number of common shares. To cover the option exercise price and applicable taxes, 10,864 shares were sold, with additional open‑market sales of 7,100 shares at a weighted average price of $12.1113 and 14,884 shares at a weighted average price of $11.8978. After these transactions, the director held 98,417 shares of common stock directly and no remaining derivative securities from this option grant.
Emergent BioSolutions (EBS) reported an insider transaction on a Form 4 for its SVP, Bioservices. On 11/11/2025, 610 shares of common stock were withheld under transaction code F, which represents shares withheld to cover taxes upon the vesting and settlement of restricted stock units. The shares were valued at $10.88 for withholding purposes. Following this administrative transaction, the officer directly beneficially owns 103,082 shares of EBS common stock.
Emergent BioSolutions (EBS) — Form 4 insider transaction. A director reported selling 17,801 shares of common stock on 11/10/2025 at a weighted average price of $10.54, with trade prices ranging from $10.33 to $10.79. The sale was executed under a Rule 10b5-1 trading plan dated August 11, 2025, established to cover tax obligations from RSUs that vested on October 2, 2025. Following the transaction, the reporting person beneficially owns 119,858 shares.
Emergent BioSolutions (EBS): Director sale reported. A director sold 8,552 shares of common stock on 11/07/2025 at $10.00 per share in an open-market transaction coded “S.” The trade was executed under a Rule 10b5-1(c) trading plan adopted on August 8, 2025. Following the sale, the director beneficially owns 88,980 shares held directly.
Emergent BioSolutions (EBS) disclosed an insider administrative transaction by its EVP and Chief Financial Officer. On 10/15/2025, 4,995 common shares were withheld (Transaction Code F) at $9.6 to cover taxes upon vesting and settlement of restricted stock units. After this transaction, the officer directly beneficially owns 291,497 shares.
Emergent BioSolutions (EBS) executive Michael M. Trova, EVP, Quality & Ethics, and CPL, sold 30,608 shares of common stock at $10.00 on 10/07/2025 pursuant to a Rule 10b5-1(c) trading plan adopted on December 2, 2024. Following the sale, he beneficially owns 144,319 shares.
The filing notes it was submitted late due to an inadvertent administrative error.